NCT00176436View on ClinicalTrials.gov

Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions
Schizophrenia
Interventions
BEHAVIORAL

Diet support group

Diet support group weekly and exercise sessions 3 times/week, placebo medication

BEHAVIORAL

Group counseling and exercise

Support group weekly and exercise sessions 3 times/week for 24 weeks

Trial Locations (1)

21228

Maryland Psychiatric Research Center, Catonsville

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

University of Maryland, Baltimore

OTHER

NCT00176436 - Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients | Biotech Hunter | Biotech Hunter